A phase I study of T900607 given once every three weeks in patients with advanced refractory cancer. A National Cancer Institute of Canada-Clinical Trials Group Study (NCIC CTG-IND 130)
Year: 2001
Type: article
Source: European Journal of Cancer
Authors: K.A. Gelmon, K. Belanger, C. Britton, D. Soulières, S. Janke, J. Dionne, J. Powers, L.K. Seymour, J. McNally
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2092208452